Please assess the completion status of the following clinical trial:

Trial Title: Sitagliptin Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has type 2 diabetes mellitus~* Males~* Females who are highly unlikely to become pregnant~* Patients poorly controlled while taking one or two oral antidiabetic medications~Exclusion Criteria:~* Patient has a history of type 1 diabetes mellitus or history of ketoacidosis~* Patient required insulin therapy within the prior 8 weeks~* Patient is on or has been taking Thiazolidinediones (TZDs) such as Actos® (pioglitazone) or Avandia® (rosiglitazone) or is on or has been taking Byetta® (exenatide) within the prior 12 weeks of the screening visit

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 78 Years
- Healthy Volunteers: f

Study Arms:
- sitagliptin 100 mg once a day (q.d.)/metformin ≥1500 mg a day (Type: EXPERIMENTAL): None
- sitagliptin 100 mg placebo q.d./ metformin ≥ 1500 mg/day (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).